A Phase 2, Open Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine (CX 2009) in Advanced HR Positive/HER2 Negative Breast Cancer and of Praluzatamab Ravtansine as Monotherapy and in Combination with Pacmilimab (CX 072) in Advanced Triple Negative Breast Cancer (CTMX 2009 002)
For more information about the trial above please contact the study team:
Principal Investigator, Frank Brescia, at firstname.lastname@example.org.
Study Coordinator, Alexandria Green, at email@example.com.
Trial opened at the following institutions: Medical University of South Carolina